Cargando…

Fork Protection and Therapy Resistance in Hereditary Breast Cancer

The BRCA-Fanconi anemia (FA) pathway preserves the genome and suppresses cancer and is a main determinant of chemotherapeutic efficacy. The hereditary breast cancer genes BRCA1 and BRCA2 function in DNA double-strand break repair mediating distinct steps of homologous recombination (HR). More recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantor, Sharon B., Calvo, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041132/
https://www.ncbi.nlm.nih.gov/pubmed/29472318
http://dx.doi.org/10.1101/sqb.2017.82.034413
_version_ 1783338946364702720
author Cantor, Sharon B.
Calvo, Jennifer A.
author_facet Cantor, Sharon B.
Calvo, Jennifer A.
author_sort Cantor, Sharon B.
collection PubMed
description The BRCA-Fanconi anemia (FA) pathway preserves the genome and suppresses cancer and is a main determinant of chemotherapeutic efficacy. The hereditary breast cancer genes BRCA1 and BRCA2 function in DNA double-strand break repair mediating distinct steps of homologous recombination (HR). More recently, independent of DNA repair, functions in the replication stress response have come to light, providing insight as to how the BRCA-FA pathway also balances genome preservation with proliferation. The BRCA-FA proteins associate with the replisome and contribute to the efficiency and recovery of replication following perturbations that slow or arrest DNA replication. Although the full repertoire of functions in the replication stress response remains to be elucidated, the function of BRCA1 and BRCA2 in protecting stalled replication forks contributes along with HR to the sensitivity of BRCA-associated tumors to chemotherapy. Moreover, chemoresistance evolves from restoration of either HR and/or fork protection. Although mechanisms underlying the restoration of HR have been characterized, it remains less clear how restoration of fork protection is achieved. Here, we outline mechanisms of “rewired” fork protection and chemotherapy resistance in BRCA cancer. We propose that mechanisms are linked to permissive replication that limits fork remodeling and therefore opportunities for fork degradation. Combating this chemoresistance mechanism will require drugs that inactivate replication bypass mechanisms.
format Online
Article
Text
id pubmed-6041132
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-60411322018-07-11 Fork Protection and Therapy Resistance in Hereditary Breast Cancer Cantor, Sharon B. Calvo, Jennifer A. Cold Spring Harb Symp Quant Biol Article The BRCA-Fanconi anemia (FA) pathway preserves the genome and suppresses cancer and is a main determinant of chemotherapeutic efficacy. The hereditary breast cancer genes BRCA1 and BRCA2 function in DNA double-strand break repair mediating distinct steps of homologous recombination (HR). More recently, independent of DNA repair, functions in the replication stress response have come to light, providing insight as to how the BRCA-FA pathway also balances genome preservation with proliferation. The BRCA-FA proteins associate with the replisome and contribute to the efficiency and recovery of replication following perturbations that slow or arrest DNA replication. Although the full repertoire of functions in the replication stress response remains to be elucidated, the function of BRCA1 and BRCA2 in protecting stalled replication forks contributes along with HR to the sensitivity of BRCA-associated tumors to chemotherapy. Moreover, chemoresistance evolves from restoration of either HR and/or fork protection. Although mechanisms underlying the restoration of HR have been characterized, it remains less clear how restoration of fork protection is achieved. Here, we outline mechanisms of “rewired” fork protection and chemotherapy resistance in BRCA cancer. We propose that mechanisms are linked to permissive replication that limits fork remodeling and therefore opportunities for fork degradation. Combating this chemoresistance mechanism will require drugs that inactivate replication bypass mechanisms. 2018-02-22 2017 /pmc/articles/PMC6041132/ /pubmed/29472318 http://dx.doi.org/10.1101/sqb.2017.82.034413 Text en http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.
spellingShingle Article
Cantor, Sharon B.
Calvo, Jennifer A.
Fork Protection and Therapy Resistance in Hereditary Breast Cancer
title Fork Protection and Therapy Resistance in Hereditary Breast Cancer
title_full Fork Protection and Therapy Resistance in Hereditary Breast Cancer
title_fullStr Fork Protection and Therapy Resistance in Hereditary Breast Cancer
title_full_unstemmed Fork Protection and Therapy Resistance in Hereditary Breast Cancer
title_short Fork Protection and Therapy Resistance in Hereditary Breast Cancer
title_sort fork protection and therapy resistance in hereditary breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041132/
https://www.ncbi.nlm.nih.gov/pubmed/29472318
http://dx.doi.org/10.1101/sqb.2017.82.034413
work_keys_str_mv AT cantorsharonb forkprotectionandtherapyresistanceinhereditarybreastcancer
AT calvojennifera forkprotectionandtherapyresistanceinhereditarybreastcancer